ArticlePreventive medicine reports2025

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.